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CPISAbstract Ventilator-associated pneumonia (VAP) is a complication in as many as 28% of patients
who receive mechanical ventilation. Studies have consistently shown that a delay in diagnosis and
treatment increases the mortality risk.
Aim of the work: The aim of this work is to elucidate the role of the serum endocan in the diag-
nosis and the prognosis of ventilator associated pneumonia.
Methods: Forty-two VAP patients, 20 non VAP ICU (on mechanical ventilation) admitted
patients and 20 healthy control subjects of similar age and sex were included in the study.
Endocan levels in serum samples were measured in all subjects.
Results: There was a highly statistically signiﬁcant difference (p value <0.001) between VAP
patients on one side and non VAP-ICU patients and healthy control subjects on the other side
regarding the mean values of endocan. Also, the mean values of endocan were statistically signiﬁ-
cantly higher (p< 0.001) among the dead VAP group than the survivor VAP group. There was a
high statistically positive correlation (p value <0.001) between mortality prediction scores
(APACHE II (R= 0.549), CRIP (R= 0.599) and SOFA (R= 0.517)) and endocan serum levels.
Conclusions: This study found increased endocan serum levels among VAP patients. We suggest
a role for endocan in the diagnosis and prediction of the prognosis of VAP patients.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Ventilator-associated pneumonia (VAP) is pneumonia that
develops 48 h or longer after mechanical ventilation and is
given by means of an endotracheal tube or tracheostomy.
Ventilator-associated pneumonia (VAP) results from theinvasion of the lower respiratory tract and lung parenchyma
by microorganisms. Intubation compromises the integrity of
the oropharynx and trachea and allows oral and gastric secre-
tions to enter the lower airways [1].
Ventilator associated pneumonia (VAP) is a complication
in as many as 28% of patients who receive mechanical ventila-
tion. The incidence of VAP increases with the duration of
mechanical ventilation. Estimated rates are 3% per day for
the ﬁrst 5 days, 2% per day for days 6–10, and 1% per day
after day 10 [2].rculosis.
866 A.A. El Halim, M. SayedThe crude mortality rate of VAP is 27–76%. Studies have
consistently shown that a delay in starting appropriate and
adequately dosed antibiotic therapy increases the mortality
risk. One of the causes of the high mortality rate is the diagnos-
tic delay [1,3,4].
Unlike community-acquired pneumonia, it may be difﬁcult
to determine whether pneumonia has developed in a hospital-
ized ventilator-dependent patient. Symptoms and signs usually
are not conclusive. Although the plain chest roentgenogram
remains an important component in the evaluation of hospital-
ized patients with suspected pneumonia, it is most helpful
when it is normal and rules out pneumonia. Microscopy eval-
uation and culture of tracheal secretions and/or expectorated
sputum are also frequently inconclusive for patients clinically
suspected of having pneumonia, because the upper respiratory
tract of most patients in the ICU is colonized with potential
pulmonary pathogens, whether or not parenchymal pul-
monary infection is present [5,6].
Endocan is a novel endothelium derived soluble dermatan
sulfate proteoglycan (PG) [7,8]. It is encoded by the ESM1
gene [9,10]. This gene is mainly expressed in the endothelial
cells in human lung and kidney tissues. The expression of this
gene is regulated by cytokines, suggesting that it may play a
role in endothelium dependent pathological disorders [11].
Sepsis and inﬂammation have associated endothelial dys-
function ranging from vasodilation, edema to coagulopathy,
ischemia, and organ failure. Since inﬂammatory mediators
(IL-1, TNF-a) induce endocan expression, blood levels of this
soluble PG may closely reﬂect the presence and severity of
inﬂammation as well as the response to therapy [10]. De
Freitas Caires et al. have recently described elevated blood levels
of cathepsin G-cleaved endocan in patients with sepsis. This
14 kDa circulating protein (p14) is the fragment of endocan
speciﬁcally cleaved by cathepsin G, a neutrophil-derived serine
protease [12]. In another study, Scherpereel et al. observed that
circulating endocan levels in blood was related to the severity of
sepsis and also reﬂected the outcome of the patients [13].
Aim of the work
The aim of this work is to elucidate the role of the serum endo-
can in the diagnosis and the prognosis of ventilator associated
pneumonia.
Subjects and methods
This study was conducted at the ICU of our university hospi-
tals. Consent was taken from each included subject. The study
included 3 groups of subjects (see Table 1):
Group 1: It included 42 VAP patients that were admitted to
the ICU. The mean age was 58.09 ± 13.07. There
were 27 (64.28%) males and 15 (35.72%) females.
Group 2: It included 20 non VAP ICU admitted patients
(on mechanical ventilation). The mean age was
56.90 ± 10.54. There were 12 (60%) males and
8 (40%) females.
Group 3: It included 20 healthy control subjects. The mean
age was 53.85 ± 11.26. There were 13 (65%)
males and 7 (35%) females.The three groups were matched for age and sex
(p value >0.05).
All subjects included in this study underwent the following:
1. Complete history taking and physical examination.
2. Chest X-ray examination.
3. Complete blood picture (CBC), C reactive protein (CRP),
liver and kidney functions tests
4. Arterial blood gases analysis (ABGs).
5. Acute Physiology and Chronic Health Evaluation II
(APACHE II) score was calculated for patient groups only.
6. The Sequential Organ Failure Assessment score (SOFA)
was calculated for patient groups only.
7. The Clinical Pulmonary Infection Score (CPIS) was calcu-
lated for patient groups only
8. Measurement of endocan serum levels: This was done in all
subjects included in this study. Blood samples were taken
and the sera were separated and stored at 80 C for
further endocan analysis. Endocan levels were determined
with the commercially available enzyme-linked immune-
sorbent assay (ELISA; LUNGINNOV Systems, Lille,
France) [12]. For VAP patients endocan measurement
was done on the ﬁrst day of diagnosis (for comparing with
other subject groups) and then repeated on the 7th day of
diagnosis.
Pneumonia was classiﬁed as VAP if it occurred after 48 h
of mechanical ventilation and was not incubated before the
initiation of the mechanical ventilation. Early-onset VAP
was deﬁned as that occurring during the ﬁrst 4 days on
mechanical ventilation, whereas VAP develops thereafter
was classiﬁed as late-onset [8]. A diagnosis of pneumonia
was suspected when a new, persistent inﬁltrate, consolidation,
cavitation or pleural effusion was seen on chest X-rays and at
least two of the following were observed: a body temperature
below 36 C or above 38 C; a white blood cell count lower
than 4000/mm3 or higher than 11,000/mm3; and macroscopi-
cally purulent tracheal aspirate. Tracheal aspirate was classi-
ﬁed as purulent or nonpurulent after visual inspection.
Tracheal aspirate for quantitative culture had been obtained
before antimicrobial treatment was started. Tracheal aspirate
cultures yielding P105 CFU/ml were considered positive. We
calculated the clinical pulmonary infection score (CPIS).
Patients were assumed to have VAP when the CPIS was
>6. Patients received a diagnosis of VAP only after other
medical conditions to which the presenting symptoms, signs
or radiological ﬁndings could be attributed had been ruled
out. For all patients in whom the clinical suspicion of VAP
was conﬁrmed, empirical antimicrobial therapy was started
immediately and modiﬁed after culture results if needed.
Patients were followed until resolution of pneumonia or
death [9].
Exclusion criteria
Any patient that had any one of the following was excluded
from this study: (1) Age below 18 years; (2) The development
of pneumonia within 48 h of the beginning of mechanical ven-
tilation; (3) Evidence of bacterial infection elsewhere; (4)
Immuno-suppression; (5) Expected early death.
Table 3 Comparison between different subject groups regard-
ing initial endocan levels (ng/ml).
Groups Mean ± SD (ng/ml) p value
1. VAP patients 11.37 ± 2.53 1 vs. 2 < 0.01
2. Non VAP patients 5.07 ± 3.50 1 vs. 3 < 0.01
3. Control subjects 4.12 ± 2.9 2 vs. 3 > 0.05
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Statistical analysis was performed with the Statistical Package
for the Social Sciences, version 16 for Windows (SPSS Inc.,
Chicago, IL, USA). Values of p< 0.05 were considered statis-
tically signiﬁcant.
Results
The total duration of mechanical ventilation among patients
with VAP was 15.35 ± 9.21 days compared with
10.67 ± 8.52 days in patients without VAP (p value < 0.01).
There were 15 (35.71%) early onset VAP patients and 27
(64.29%) late onset VAP patients.
The causative microbes among VAP patients are shown in
Table 2.
There was highly statistically signiﬁcant difference (p
value < 0.001) between VAP patients (11.37 ± 2.53 ng/ml)
on one side and non VAP-ICU (5.07 ± 3.50 ng/ml) patients
and healthy control subjects (4.12 ± 2.9 ng/ml) on the other
side regarding the mean values of endocan (Table 3 and
Fig. 1). No statistically signiﬁcant difference (p value >0.05)Table 1 Some characteristic data for the subjects included in
this study.
VAP patients
(N= 42)
Non VAP
patients
(N= 20)
Healthy
subjects
(N= 20)
Age
(Mean ± SD)
58.09 ± 13.07 56.90 ± 10.54 53.85 ± 11.26
Sex (Male/
Female)
27/15 12/8 13/7
CRP (mg/L) 160.4 ± 4.7 28.53 ± 2.6 5.38 ± 1.1
WBC (·103/lL) 14.5 ± 3.53 9.6 ± 0.45 6.5 ± 1.04
APACHE II 24.11 ± 4.57 16 ± 3.25 NA
SOFA 7.88 ± 2.92 3.56 ± 2.04 NA
Associated conditions
COPD 8 5 0
DM 10 4 0
Renal failure 3 2 0
Heart diseases 11 5 0
Malignancy 7 2 0
Neurologic
diseases
3 1 0
Liver cirrhosis 3 2 0
Table 2 Microbiological proﬁle among the VAP patients.
Microbes No. of the VAP patients (%)
Staphylococcus aureus 7 (16.67)
Pseudomonas aeruginosa 5 (11.91)
Klebsiella pneumoniae 4 (9.52)
Haemophilus inﬂuenzae 3 (7.14)
Acinetobacter 2 (4.76)
Enterobacter 1 (2.38)
Proteus 1 (2.38)
Serratia 1 (2.38)
Mixed 2 (4.76)
Unidentiﬁed 16 (38.10)
Figure 1 Comparison between different subject groups regard-
ing initial endocan levels (ng/ml).in the mean values of endocan was present between non
VAP-ICU patients (5.07 ± 3.50 ng/ml) and healthy control
subjects (4.12 ± 2.9 ng/ml) (Table 3 and Fig. 1).
22 (52.38%) patients out of 42 VAP patients survived while
20 (47.62) patients died. No patient died in the ﬁrst 7 days after
diagnosis.
The mean values of endocan were statistically signiﬁcantly
higher (p value <0.001) among the dead VAP group than
the survivor VAP group on both ﬁrst day (12.50 ± 2.74 ng/ml
vs. 10.35 ± 1.86 ng/ml, respectively) and 7th day measure-
ments (24.33 ± 7.14 ng/ml vs. 5.93 ± 1.56 ng/ml respectively)
(Table 4 and Fig. 2).
The mean values of endocan increased signiﬁcantly (from
(12.50 ± 2.74 ng/ml to 24.33 ± 7.14 ng/ml) among dead
group while it decreased signiﬁcantly (from
12.50 ± 2.74 ng/ml to 5.93 ± 1.56 ng/ml) among the survivor
group on repeated testing on the 7th day in comparison with
the ﬁrst day measurement (Table 4 and Fig. 2).
There was a high statistically positive correlation (p value
<0.001) between mortality prediction scores (APACHE II
(R= 0.549), CRIP (R= 0.599) and SOFA (R= 0.517)) and
endocan serum levels.
Discussion
In this study, there was a highly statistically signiﬁcant differ-
ence (p value <0.001) between VAP patients
(11.37 ± 2.53 ng/ml) on one side and non VAP-ICU
(5.07 ± 3.50 ng/ml) patients and healthy control subjects
(4.12 ± 2.9 ng/ml) on the other side regarding the mean values
of endocan. These results are in agreement with those of other
investigators. Scherpereel et al. [13] observed that circulating
endocan levels in the blood was related to the severity of sepsis
and also reﬂected the outcome of the patient. De Freitas Caires
et al. [12] have recently described elevated blood levels of
cathepsin G-cleaved endocan in patients with sepsis. They
Table 4 Comparison of some measurements between survivor and dead groups among VAP patients.
Outcome APACHE II SOFA CPIS Endocan 1st Endocan 7th
Survivors (No = 22) Mean ± SD 22.31 ± 3.73 6.40 ± 2.90 7.68 ± 1.04 10. 35 ± 1.86 5.93 ± 1.56
Died (No = 20) Mean ± SD 26.10 ± 4.66 9.50 ± 1.96 9.25 ± 2.02 12.50 ± 2.74 24.33 ± 7.14
p value P< 0. 05 P< 0. 001 P< 0. 001 P< 0. 05 P< 0. 001
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Figure 2 Comparison of mean endocan levels between survivor
and dead groups among VAP patients.
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plasma levels of endocan, whereas in the control subjects endo-
can was undetectable. In another study by Kao et al. [14] the
plasma concentration of endocan, but not CRP or the WBC
count, was correlated with the severity of pneumonia. Cox
and his colleagues [15] measured plasma endocan, ICAM,
and VCAM concentrations among 17 healthy male volunteers
before and 4 h after the administration of 2 ng/kg lipopolysac-
charide (LPS). They found that plasma levels of all measured
cytokines, endocan, ICAM, and VCAM concentrations signif-
icantly increased after LPS administration. They suggested
that endocan could be a novel marker of endothelial dysfunc-
tion in inﬂammatory conditions associated with endotoxemia.
These results can be explained by the ﬁndings that sepsis and
inﬂammation have associated with excess release of the inﬂam-
matory mediators like IL-1, TNF-a that induce endocan
expression and blood levels of it may closely reﬂect the pres-
ence and severity of inﬂammation as well as the response to
therapy [10].
Our study revealed the mean values of endocan were statis-
tically signiﬁcantly higher (p value <0.001) among the dead
VAP group than the survivor VAP group on both ﬁrst day
(12.50 ± 2.74 ng/ml vs. 10.35 ± 1.86 ng/ml respectively) and
7th day measurements (24.33 ± 7.14 ng/ml vs.
5.93 ± 1.56 ng/ml respectively). Also the mean values of endo-
can increased signiﬁcantly (from (12.50 ± 2.74 ng/ml to
24.33 ± 7.14 ng/ml) among dead group while decreased signif-
icantly (from 12.50 ± 2.74 ng/ml to 5.93 ± 1.56 ng/ml) among
the survivor group on repeated testing on the 7th day in com-
parison with the ﬁrst day measurement Other studies showed
similar results. Palmiere et al. [16] investigated endocan, pro-
calcitonin and C-reactive protein in postmortem serum from
femoral blood in a series of sepsis-related fatalities and control
individuals who underwent medicolegal investigations.
Postmortem serum endocan concentrations were signiﬁcantly
higher in the sepsis group. Mihajlovic and his group [17] found
the concentration of endocan was signiﬁcantly higher in thegroup of patients with sepsis induced organ failure, MODS
development and in the group of non-survivors in contrast
to group with less severe form of the disease, without multior-
gan failure, and in contrast to a group of survivors (p< 0.05).
Values of areas under the ROC curves showed that endocan
levels had good discriminating power for a more severe course
of sepsis, MODS development and possible discriminating
power for mortality prediction (AUC: 0.81, 0.67, 0.71 retro-
spectively), better than PCT for fatality (AUC:053) and better
than APACHE II (AUC:0.55) and SOFA (AUC:0.57) scores
for organ failure. These results are explained intuitively by that
the severe and non respondent pneumonia among dead
patients is associated with high bacterial and toxin loads that
stimulate release of the inﬂammatory mediators that induce
excess release of endocan.
Our study found a high statistical positive correlation (p
value <0.001) between mortality prediction scores
(APACHE II (R= 0.549), CRIP (R= 0.599) and SOFA
(R= 0.517)) and endocan serum levels. These results are in
agreement with those of other studies. A recent study reported
that plasma endocan was superior to C-reactive protein and
white blood cell count in evaluating the severity of pneumonia
and had better correlation with pneumonia severity scores such
as pneumonia severity index, CURB-65, and APACHE II
scores [14]. Tang et al. [18] found that endocan levels signiﬁ-
cantly correlated with the APACHE II score in the ARDS
patients (R= 0.676, P= 0.000). Endocan was signiﬁcantly
higher in nonsurvivors than in survivors (P= 0.017). Other
investigators found similar results in different diseases [19–21].
Conclusions
This study found increased endocan serum levels among VAP
patients. We suggest a role for endocan in the diagnosis and
prediction of the prognosis of VAP patients. We recommend
other larger studies to augment our ﬁndings.
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